Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction - PubMed (original) (raw)
. 2005 Nov;289(5):H1960-7.
doi: 10.1152/ajpheart.00328.2005. Epub 2005 Jul 1.
Affiliations
- PMID: 15994860
- DOI: 10.1152/ajpheart.00328.2005
Free article
Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction
Xichun Yu et al. Am J Physiol Heart Circ Physiol. 2005 Nov.
Free article
Abstract
Arrhythmia-prone subepicardial border zone (EBZ) tissue demonstrates decreased G protein receptor kinase 2 (GRK2) activity and increased sensitivity to isoproterenol 6-24 h after coronary artery ligation (CAL) in the dog. With the use of a semiquantitative immunofluorescence technique, the relative fluorescence intensity (RF) of GRK2 in EBZ decreased to 24% of that in a remote site (RS) (P < 0.01, n = 30 cells from 3 dogs), whereas GRK5 RF did not change. Confocal studies of cardiac tissue from transgenic mice overexpressing GRK2 validated the use of a semilogarithmic relationship between RF and GRK2 activity. As shown with the use of quantitative real-time RT-PCR, both GRK2 and GRK5 mRNA were not decreased at 24 h in EBZ (n = 6 dogs) relative to RS control, indicating that the decrease of GRK2 in the EBZ is likely due to posttranscriptional degradation following CAL. Pretreatment of six dogs with the selective proteasome inhibitor bortezomib provided 100% (EBZ) and 50% (infarct) protection against loss of GRK2 at 24 h. There was an absence of rapid (>300 beats/min) and very rapid (>360 beats/min) ventricular triplets that are highly predictive of sudden cardiac death during ECG monitoring in the bortezomib-pretreated animals in contrast to nonpretreated infarcted animals. We have demonstrated that the dramatic decrease in GRK2 in cardiac ischemic tissue can be largely blocked by prior proteasome blockade and that this is associated with significant cardioprotection against malignant ventricular tachyarrhythmias.
Similar articles
- Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Huang S, Patterson E, Yu X, Garrett MW, De Aos I, Kem DC. Huang S, et al. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1298-303. doi: 10.1152/ajpheart.00765.2007. Epub 2008 Jan 11. Am J Physiol Heart Circ Physiol. 2008. PMID: 18192226 - Ischemic inactivation of G protein-coupled receptor kinase and altered desensitization of canine cardiac beta-adrenergic receptors.
Yu X, Zhang M, Kyker K, Patterson E, Benovic JL, Kem DC. Yu X, et al. Circulation. 2000 Nov 14;102(20):2535-40. doi: 10.1161/01.cir.102.20.2535. Circulation. 2000. PMID: 11076829 - Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats.
Vinge LE, Øie E, Andersson Y, Grøgaard HK, Andersen G, Attramadal H. Vinge LE, et al. Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2490-9. doi: 10.1152/ajpheart.2001.281.6.H2490. Am J Physiol Heart Circ Physiol. 2001. PMID: 11709416 - Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction.
Schmitt H, Cabo C, Coromilas JC, Wit AL. Schmitt H, et al. J Cardiovasc Electrophysiol. 2001 Sep;12(9):1025-33. doi: 10.1046/j.1540-8167.2001.01025.x. J Cardiovasc Electrophysiol. 2001. PMID: 11573692 - The proteasome.
Dalton WS. Dalton WS. Semin Oncol. 2004 Dec;31(6 Suppl 16):3-9; discussion 33. doi: 10.1053/j.seminoncol.2004.10.012. Semin Oncol. 2004. PMID: 15799238 Review.
Cited by
- Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases.
Liu H, Ma H, Zeng X, Wu C, Acharya S, Sudan SK, Zhang X. Liu H, et al. Int J Mol Sci. 2023 Jun 12;24(12):10031. doi: 10.3390/ijms241210031. Int J Mol Sci. 2023. PMID: 37373182 Free PMC article. - Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost.
Efentakis P, Andreadou I, Iliodromitis KE, Triposkiadis F, Ferdinandy P, Schulz R, Iliodromitis EK. Efentakis P, et al. Int J Mol Sci. 2022 Nov 15;23(22):14121. doi: 10.3390/ijms232214121. Int J Mol Sci. 2022. PMID: 36430599 Free PMC article. Review. - Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.
Tamargo J, Caballero R, Delpón E. Tamargo J, et al. Drug Saf. 2022 Feb;45(2):101-126. doi: 10.1007/s40264-021-01132-5. Epub 2022 Jan 13. Drug Saf. 2022. PMID: 35025085 Review. - Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion.
Penela P, Inserte J, Ramos P, Rodriguez-Sinovas A, Garcia-Dorado D, Mayor F Jr. Penela P, et al. EBioMedicine. 2019 Oct;48:605-618. doi: 10.1016/j.ebiom.2019.09.019. Epub 2019 Oct 5. EBioMedicine. 2019. PMID: 31594751 Free PMC article. - G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases.
Murga C, Arcones AC, Cruces-Sande M, Briones AM, Salaices M, Mayor F Jr. Murga C, et al. Front Pharmacol. 2019 Feb 19;10:112. doi: 10.3389/fphar.2019.00112. eCollection 2019. Front Pharmacol. 2019. PMID: 30837878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials